GlobeNewswire

DoubleVerify Partners with MoPub to Combat Mobile Ad Fraud

Del

Partnership extends DV fraud coverage across MoPub’s mobile app exchange

NEW YORK, Jan. 08, 2019 (GLOBE NEWSWIRE) -- DoubleVerify ("DV"), the leading independent provider of marketing measurement software and analytics, today announced a partnership with MoPub, a leading provider of monetization solutions for mobile app publishers and developers around the globe. As part of the partnership, DoubleVerify will provide fraud detection and reporting for mobile app campaigns across MoPub’s exchange – extending quality coverage for global advertisers and enabling MoPub to continuously refine the quality of its mobile ad inventory.

“DV’s partnership with MoPub reflects our commitment to provide consistent, comprehensive quality coverage for global brand advertisers,” said Matt McLaughlin, COO at DoubleVerify. “With ad spend increasingly concentrated in mobile, it’s imperative that brands have clarity into the quality of mobile app inventory. We are proud of our partnership with MoPub, which expands the footprint of our fraud prevention capabilities and further distinguishes DV as the leader for mobile app verification.”

As part of its industry-leading mobile app fraud solution, DoubleVerify identifies and screens the most significant types of in-app fraud, including background ad activity, hidden ads, app misrepresentation (spoofing) and measurement manipulation. In March 2017, DV received Media Rating Council (MRC) accreditation for its technology to detect and block sophisticated invalid traffic (SIVT) for mobile app video and display advertising.

“Traffic quality is a top priority for MoPub and our clients, since invalid traffic (IVT) is an industry-wide concern,” said Boris Logvinskiy, MoPub’s Head of Product. “Partnerships are crucial to the effort.  We believe that MRC-accredited vendors like DoubleVerify offer the expertise, technology, data integrity and service needed to help us maintain a clean exchange for the trillions of ad requests we facilitate.”

For more information about DoubleVerify’s mobile app capabilities, contact sales@doubleverify.com.

About DoubleVerify

DoubleVerify is the leading independent provider of marketing measurement software, data and analytics that authenticates the quality and effectiveness of digital media for the world's largest brands and media platforms. DV provides media transparency and accountability to deliver the highest level of impression quality for maximum advertising performance. Since 2008, DV has helped hundreds of Fortune 500 companies gain the most from their media spend by delivering best in class solutions across the digital ecosystem, helping to build a better industry. Learn more at doubleverify.com.

About MoPub

MoPub, a Twitter company, provides monetization solutions for mobile app publishers and developers around the globe. Our flexible network mediation solution, leading mobile programmatic exchange, and years of expertise in mobile app advertising mean publishers trust us to help them maximize their ad revenue and control their user experience. MoPub Marketplace, our in-app exchange, enables DSPs and marketers to reach their audience through a powerful interface, strict supply quality and viewability measurement, and a transparent bidding experience. MoPub’s world-class service brings strategic business insights and data-driven expertise to meet the evolving needs of publishers and buyers.

PR Contact:
Chris Harihar of Crenshaw Communications, on behalf of DoubleVerify
chris@crenshawcomm.com
212.367.9748

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

WillScot to Participate at the Barclays Industrial Select Conference16.1.2019 21:00Pressemelding

BALTIMORE, Jan. 16, 2019 (GLOBE NEWSWIRE) -- WillScot Corporation (“WillScot”)(NASDAQ: WSC), the specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced that Brad Soultz, President and Chief Executive Officer, and Tim Boswell, Chief Financial Officer, will present at the Barclays Industrial Select Conference at the Loews Miami Beach Hotel in Miami, Florida, on Wednesday, Feb. 20, 2019. The presentation will take place at 10:20 a.m. EST. About Williams Scotsman Headquartered in Baltimore, Maryland, WillScot Corporation is the public holding company for the WillScot family of companies in the United States, Canada and Mexico. WillScot Corporation trades on the NASDAQ stock exchange under the ticker symbol “WSC.” WillScot is the specialty rental services market leader providing innovative modular space and portable storage solutions across North America. It is the modular space supplier of choice for t

CCI has been retained by Waterloo Brewing to obtain Cannabis Licence16.1.2019 16:00Pressemelding

TORONTO, Jan. 16, 2019 (GLOBE NEWSWIRE) -- Cannabis Compliance Inc., (CCI) of Toronto, Ontario is pleased to announce they have partnered with Waterloo Brewing to help them obtain their Research and standard Processing Licence to develop cannabis-infused beverages. “CCI is working with Waterloo Brewing on the early stages of the application process and we are confident that we will help them achieve their desired licenses in time to be an active player in this growing sector of the cannabis industry”, said Brian Wagner, CEO and Founder, Cannabis Compliance Inc. “We are here to guide our clients through the early stages of the licensing process and for the many Health Canada requirements thereafter.” CCI offers end to end business solutions for cannabis companies large and small. Our team brings with them years of experience in the quality, regulatory, security and cultivation sectors, and supports manufacturers and retailers through regulatory challenges. As the world’s largest and mos

Aryaka Announces Expansion of Senior Leadership Team with New Chief Revenue Officer, Chief Transformation Officer and Chief Marketing Officer16.1.2019 15:00Pressemelding

Karen Freitag, Michelle Owczarzak, & Shashi Kiran join Aryaka to address significant growth and assist global enterprises in adopting managed connectivity as-a-service SAN MATEO, Calif., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Aryaka®, announced today the appointment of several new executive hires to the company’s leadership team, including Karen Freitag (Chief Revenue Officer), Michelle Owczarzak (Chief Transformation Officer), and Shashi Kiran (Chief Marketing Officer). “Connectivity is the lifeblood of the global enterprise and Aryaka is the industry benchmark for secure managed connectivity worldwide. We are excited to have experienced industry veterans join our robust executive leadership team and continue to help build upon the immense success and growth that Aryaka has seen in recent years,” said Matt Carter, CEO of Aryaka. “As our customers expand globally, embrace SD-WAN, or move to the cloud, we’re becoming the de facto choice for their needs to make this happen better, faster, che

ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors16.1.2019 07:00Pressemelding

Pyrrolobenzodiazepine-based antibody drug conjugate targets AXL, a receptor tyrosine kinase highly expressed in solid tumors LAUSANNE, Switzerland, Jan. 16, 2019 (GLOBE NEWSWIRE) -- ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been dosed in its Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and anti-tumor activity of ADCT-601 in patients with selected solid tumors that are locally advanced or metastatic. ADCT-601 is an ADC composed of a humanized monoclonal antibody against human AXL, conjugated using GlycoConnect™ site specific conjugation technology to a pyrrolobenzodiazepine (PBD) dimer toxin. In preclinical studies, ADCT-601 demonstrated potent and specific in vitro and in vivo anti-tumor activity in multiple cancer-derived models with different levels of AXL expression, and was stable and well tolerated

GSA Europe’s Managing Director Elected Co-lead of CEN’s TC456 Committee15.1.2019 21:12Pressemelding

SAN GWANN, Malta, Jan. 15, 2019 (GLOBE NEWSWIRE) -- GSA Europe’s Managing Director Mark Pace has been elected by the Comité Européen de Normalisation (CEN) to lead the creation of a European Union online gaming reporting standard. CEN has established Technical Committee 456 to create this standard in support of online gambling supervision. GSA Europe joined Technical Committee 456 as a Liaison Organization in 2017. The Technical Committee’s mandate from the European Commission is directly aligned with work that GSA Europe has already started, namely, to create a single standard set of data elements and single standard way in which data is provided by online gambling providers to EU Member State regulatory authorities. In addition to joining and now leading the Technical Committee’s work, GSA Europe also donated their draft Regulatory Data Set and Regulatory Reporting Interface to CEN seeking to help jump-start the Committee’s work. “Joining CEN’s TC456 as a Liaison Organization, and no

Orion Biotechnology Reports Positive Results for Colorectal Cancer in Preclinical Study15.1.2019 15:00Pressemelding

OTTAWA, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced preclinical data produced in collaboration with Charles River Laboratories, evaluating the efficacy of OB-002O (5P12-RANTES) in colorectal cancer. BALB/c mice were inoculated subcutaneously with the CT-26 colorectal cancer cell line. Three days after inoculation intraperitoneal treatment was started with OB-002O, a murine anti-PD-1 antibody, OB-002 + anti-PD-1, or saline placebo. Treatment was given daily or every third day. Treatment with OB-0020 alone led to statistically significant delayed tumor growth at multiple time-points. An even more profound effect on the decrease in mean tumor volume was observed in combination cohort where animals received both, OB-0020 and the anti-PD-1 antibody (p>0.05). “There is growing awareness of the role of CCR5 antagonism as an important component of cancer immunotherapy. OB-002O is an extremely potent CCR5 antagonist